Clinical Trial Update: A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects [Phase 1]

View source ↗

Summary

First-in-human Phase 1 trial to evaluate safety, tolerability, and pharmacology of HS-10390 in healthy subjects; the study lists IgA nephropathy and focal segme…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis
• Iga Nephropathy

Drugs mentioned

• HS-10390

Snippet

Sponsor: Hansoh BioMedical R&D Company | Conditions: IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 1 | Status: RECRUITING